INNATE PHARMA SP.ADR/1 (IDDA) — Working Capital to Net Assets Ratio
INNATE PHARMA SP.ADR/1 (IDDA) has a Working Capital to Net Assets ratio of -46.4% as of December 2025. Working capital of €10.06 Million (current assets of €46.71 Million minus current liabilities of €36.65 Million) is measured against net assets of €-21.70 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See defensive interval ratio of INNATE PHARMA SP.ADR/1 to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
INNATE PHARMA SP.ADR/1 Working Capital to Net Assets (2021–2025)
This chart shows how INNATE PHARMA SP.ADR/1's Working Capital to Net Assets ratio has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the ratio stands at -46.4%, reflecting working capital of €10.06 Million against net assets of €-21.70 Million EUR. For the complete balance sheet picture, see balance sheet size of INNATE PHARMA SP.ADR/1.
Annual Working Capital to Net Assets for INNATE PHARMA SP.ADR/1 (2021–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for INNATE PHARMA SP.ADR/1 from 2021 to 2025, covering 5 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check INNATE PHARMA SP.ADR/1 liquidity resilience to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -46.4% | €10.06 Million | €-21.70 Million | €46.71 Million | €36.65 Million | ▼ -643.6 pp |
| 2024 | 597.2% | €52.76 Million | €8.83 Million | €85.74 Million | €32.98 Million | ▲ +388.4 pp |
| 2023 | 208.8% | €108.38 Million | €51.90 Million | €148.01 Million | €39.64 Million | ▲ +26.9 pp |
| 2022 | 181.9% | €98.49 Million | €54.15 Million | €139.83 Million | €41.34 Million | ▲ +127.6 pp |
| 2021 | 54.3% | €58.37 Million | €107.44 Million | €138.26 Million | €79.89 Million | — |